Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Demand for GLP-1 drugs is soaring. Thanks to caller breakthroughs, medicines successful this class are expanding their addressable markets and treating conditions specified arsenic obstructive slumber apnea (OSA), metabolic dysfunction-associated steatohepatitis, and others, successful summation to diabetes and value management, which are possibly their astir important areas.

Eli Lilly (NYSE: LLY) is simply a person successful this space, but respective companies are looking to instrumentality its crown. One of them is Viking Therapeutics (NASDAQ: VKTX), a smaller biotech with promising GLP-1 candidates. Could Viking Therapeutics successfully situation Eli Lilly? Let's find retired which of these 2 stocks is simply a amended bargain for investors looking to capitalize connected this opportunity.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

Eli Lilly is firing connected each cylinders

Eli Lilly's tirzepatide, which mimics the enactment of some the GLP-1 and GIP hormones, is approved for diabetes, value loss, and OSA. It is by acold the company's astir important maturation operator close present and the best-selling medicine successful this niche. In the 2nd quarter, Eli Lilly's gross accrued by 48% twelvemonth implicit twelvemonth to $23 billion. Sales of Mounjaro -- the marque sanction for tirzepatide successful the diabetes marketplace -- soared 91% twelvemonth implicit twelvemonth to $9.9 billion. Zepbound's (tirzepatide's marque successful value management) gross was $4.9 billion, up 46% compared to the year-ago period.

Eli Lilly besides markets Foundayo, an oral GLP-1 that is helping grow the marketplace by attracting mostly caller patients. It isn't generating meaningful gross yet, astatine slightest by Eli Lilly's standards, but erstwhile it expands beyond value nonaccomplishment and into diabetes, OSA, and different indications, it could commencement making important contributions to top-line growth.

Eli Lilly has a heavy pipeline beyond these approved products. The astir promising is retatrutide, a medicine that posted outstanding signifier 3 objective proceedings results successful diabetes and value loss. Eli Lilly plans to petition support for retatrutide successful the archetypal 4th of 2027. Eli Lilly looks apt to support its pb successful this marketplace for the foreseeable future, and it besides has charismatic approved products and pipeline candidates successful different areas.

Viking Therapeutics has cardinal catalysts up

Viking Therapeutics is simply a clinical-stage biotech. The company's starring candidate, VK2735, looks promising. Just similar tirzepatide, VK2735 is simply a dual GLP-1 and GIP agonist. A subcutaneous mentation of the medicine is undergoing signifier 3 studies, portion the drugmaker should commencement late-stage trials for an oral formulation by year-end. Subcutaneous VK2735 posted fantabulous results successful signifier 2 studies. It led to a mean value nonaccomplishment of up to 14.7% successful 13 weeks, with nary plateau observed.